It might be that BOT got approval in June24, and in 12 months generated A$20m… some of which would include their own co-contributions (BOT’s own money!), making the treatment free for the patient.
contrasted to MSB who had half the time of BOT and generated the same amount of revenue A$20m in a quarter… compared to inception to date A$20m for BOT (12 months).
I was hoping after you asked a fair few questions of this forum and some of us giving you a decent response, you’d answer the one question asked of you?
what are your thoughts on Mesoblast’s launch of Ryoncil? Launched themselves in 3 months post approval and A$20m / US$13m sales in first quarter post launch?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)